---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-266933"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:22:35.716108+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics plans DT-818 DM1 trial H1 2026; Q3 net loss $17M; cash $206M

## Summary
- DT-818 nominated as DM1 development candidate; >90% reduction in toxic RNA foci in preclinical studies.
- Ex-US regulatory clearance obtained; Phase 1 MAD trial in Australia to start H1 2026; splicing data expected 2027.
- Q3 2025 net loss $17.0M; R&D expense $14.6M; G&A expense $4.7M.
- Cash and securities $206.0M as of Sept 30, 2025, supporting pipeline advancement.
- Board appointed Justin Gover (former CEO of GW Pharma, led $7B acquisition by Jazz) in September 2025.

## SEC filing metadata
- accession: 0001193125-25-266933
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000119312525266933/0001193125-25-266933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000119312525266933/dsgn-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-266933
- JSON: https://secwatch.observer/filing/0001193125-25-266933.json
- Plain text: https://secwatch.observer/filing/0001193125-25-266933.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.